Investment Rating - The report maintains a "Positive" investment rating for the healthcare sector [7] Core Insights - Overall, the performance of overseas CXO companies in Q3 2025 met expectations, with M segment outperforming R segment, and clinical CRO performing better than preclinical CRO [5][17] - Demand indicators show that several companies have stable or improving RFPs, new orders, and backlog orders, with Pharma demand remaining steady and Biotech demand showing slight recovery [5][17] - The biotechnology financing environment shows signs of improvement in Q3 2025 [5][17] Summary by Sections Performance Overview - Overseas CXO companies' revenue in Q3 2025 is generally in line with expectations, with M segment performing better than R segment, and clinical CRO outperforming preclinical CRO [5][17] - Revenue for CRL in Q1-3 2025 was $3.021 billion, a year-on-year decline of 0.9%, with net profit down 41.5% [23][33] Demand Trends - Demand for CRO services is gradually improving, with positive trends in RFPs and orders, which are expected to translate into performance [18] - CDMO shows strong resilience, with Lonza's CDMO business performing robustly and Samsung Biologics' revenue growing by 18% year-on-year in Q3 2025 [6][18] Company-Specific Insights - Labcorp reported a revenue of $10.436 billion in Q1-3 2025, a year-on-year increase of 7.8%, with Q3 revenue at $3.564 billion, up 8.6% [39][41] - IQVIA's revenue for Q1-3 2025 was $11.946 billion, a year-on-year increase of 4.4%, with Q3 revenue at $4.100 billion, up 5.2% [50][53] - ICON's Q3 2025 revenue was $2.043 billion, showing a year-on-year growth of 0.6% [65][69] - Medpace's Q3 2025 revenue reached $660 million, a year-on-year increase of 23.7% [73][78]